{"filings":[{"id":1343396,"accession_number":"0001493152-26-031216","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2026-06-30T13:00:43+00:00","items":["1.01","2.03","5.02","9.01"],"status":"ready","headline":"Celularity enters $1M secured loan from Barach trust; director LeVien resigns","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Loan of $1,000,000 from Philip & Daniele Barach Family Trust (affiliated with >5% owner) at 4% interest, matures in 30 days or upon receipt of proceeds from financing.","Loan secured by first-priority security interest in substantially all personal property; Robert J. Hariri subordinated his debt.","Director Vincent LeVien resigned effective June 26, 2026, not due to any disagreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1279316,"accession_number":"0001493152-26-030199","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2026-06-25T21:27:32+00:00","items":["5.02"],"status":"ready","headline":"Celularity appoints Steven Gordon as COO, Harold Fletcher as CLO; Gordon also joins Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steven N. Gordon appointed Chief Operating and Administrative Officer, effective June 19, 2026.","K. Harold Fletcher appointed Chief Legal and Strategy Officer and Corporate Secretary, effective same date.","Gordon, previously EVP Business Affairs since Jan 2026, also elected to the Board of Directors.","Fletcher, previously EVP Legal and Strategy since Jan 2026, had served as General Counsel and Chief Compliance Officer.","No family relationships or arrangements with other persons disclosed for either officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1029758,"accession_number":"0001493152-26-028519","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2026-06-12T21:15:41+00:00","items":["3.01"],"status":"ready","headline":"Celularity receives Nasdaq deficiency notice for MVLS below $35M; 180 days to comply","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Celularity on June 9, 2026, that MVLS was below $35M for 30 consecutive business days.","Company has until December 7, 2026 to regain compliance by achieving MVLS >= $35M for 10 consecutive days.","If not compliant by Dec 7, Nasdaq will issue delisting notification; company may appeal the decision.","Evaluating options including increasing stockholders' equity to at least $2.5M to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":836197,"accession_number":"0001493152-26-027132","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2026-06-03T21:22:06+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Celularity names Rick Gonzalez Chief Commercial Officer, advances longevity and cenplacel-L focus","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rick Gonzalez appointed CCO effective May 29, 2026, reporting to Chairman & CEO Robert Hariri.","Gonzalez has 20+ years biotech experience; previously CCO at Alume Biosciences, CEO at Navidea.","Company sharpens focus on longevity, regenerative medicine; cenplacel-L sees physician demand in Florida.","Out-licensed biomaterials to NexGel for up to $30M, reducing liabilities by ~$13M (previously announced)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":723716,"accession_number":"0001493152-26-025646","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2026-05-28T20:54:19+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Celularity settles Helena dispute; pays $500K cash, $500K installments, assigns $2.5M NEXGEL note","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Settlement with Helena Global resolves claims over Series A convertible preferred stock and promissory note.","Company pays $500,000 at closing plus five monthly payments of $100,000 each.","Company assigns to Helena a $2,500,000 promissory note from NEXGEL, Inc. related to biomaterials asset sale.","Holder's release of claims is conditional on full payment of cash, all installments, and note assignment.","Security agreement remains in effect until all obligations are satisfied; release only upon final payment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95195,"accession_number":"0001493152-26-018220","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2026-04-21T23:59:59+00:00","items":["1.01","2.03","3.03","5.02","8.01","9.01"],"status":"ready","headline":"Celularity closes $13.3M NexGel asset sale; Helena default notice on $1.97M note","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed asset sale to NexGel for $13.3M ($8.3M cash + $5M note), retired ~$13M debt.","Eligible for up to $20M milestones and royalties on net sales.","Helena exchanged for $1.97M note at 18%; default notice for late 10-K; potential 115% acceleration.","Co. terminated John Haines (SVP/CAO) and Stephen Brigido resigned (President, Degenerative)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108069,"accession_number":"0001493152-26-009471","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Celularity licenses biomaterials portfolio for up to $35M; retains manufacturing, cuts costs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $35M cash: $15M upfront plus $20M milestone payments based on net sales targets.","Celularity will act as exclusive manufacturer of licensed products at its New Jersey FDA-compliant facility.","Workforce reduction and organizational realignment expected to lower operating costs and sharpen focus on longevity therapeutics.","Transaction expected to close no later than April 15, 2026, subject to customary conditions including financing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108068,"accession_number":"0001493152-26-009017","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Celularity CFO Joseph DosSantos departs; John Sprague named acting CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joseph DosSantos left as SVP Finance and Acting CFO on Feb 27, 2026 for personal reasons.","John Sprague appointed Acting CFO effective same date.","No additional details on compensation or transition timeline provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108067,"accession_number":"0001493152-26-003100","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2026-01-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Celularity amends SVP Haines' agreement; severance doubled, COBRA extended, equity accelerated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Comp Committee approved amendment to John Haines' employment agreement on Jan 16, 2026.","Severance period increased from 12 to 24 months upon qualifying termination.","COBRA payment extended to 18 months from prior term.","Equity options that would vest over 24 months post-termination will vest immediately upon termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124493,"accession_number":"0001493152-25-029033","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Celularity closes $10M financing with Philip A. Barach; issues senior secured and convertible notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Gross proceeds at closing: $10.0M; potential additional $2.0M subject to conditions.","Senior secured term loan: $7.0M principal, 4% interest (12% on default), matures April 30, 2026 or upon qualified financing.","Secured convertible notes: up to $5.0M, 8% PIK interest, convertible at $1.66/share, maturity Dec 31, 2026.","Issued warrants to purchase 3,707,657 shares at $2.00/share, exercisable from June 19, 2026 to Dec 19, 2030.","Investor granted board observer rights; notes secured by first-priority liens on substantially all assets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124492,"accession_number":"0001493152-25-028560","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Celularity annual meeting: directors elected despite majority withheld; equity plan increase fails","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class I directors Peter Diamandis, Diane Parks, Geoffrey Ling elected; each received >4.5M votes for but >9.5M withheld.","Ratification of EisnerAmper LLP as auditor passed: 10,050,276 for, 31,337 against, 9,374,540 abstentions.","Proposal to increase 2021 Equity Incentive Plan by 3.5M shares failed: 4,342,023 for, 890,138 against, 9,368,069 abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124491,"accession_number":"0001493152-25-026383","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2025-12-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Celularity receives FDA warning letter over Interfyl marketing claims","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA warning letter received Dec 1, 2025, regarding marketing material for Interfyl (human connective tissue matrix).","Letter cites outcome-based and metabolic activity claims; company must limit such claims per Section 361 of CFR 1271.10.","No restriction on manufacturing, product shipment, recall, or ability to seek 510(k) clearance.","Company states no material impact on operational/financial expectations; resolution timeline uncertain.","Additional regulatory action may occur if issues not resolved to FDA's satisfaction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124490,"accession_number":"0001493152-25-019839","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["1.01","3.02","5.03","9.01"],"status":"ready","headline":"Celularity raises $2M initial tranche in $6.67M private placement of Series A Preferred and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Series A Preferred shares sold at 90% of stated value; $2M initial tranche closed Oct 24, 2025.","Up to three tranches totaling $6.67M stated value; warrants exercisable at $3.00/share for 25% of purchase price.","Conversion price lower of 110% of prior close or 95% of 7-day VWAP, floor $1.60; 5% dividend (18% on trigger event).","Proceeds used for working capital; investor capped at 4.99% beneficial ownership unless waived.","Shares issued exempt under Section 4(a)(2) and Regulation D; resale registration required within 30 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141165,"accession_number":"0001641172-25-026245","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nasdaq confirms Celularity compliant with listing rule after late 10-Qs; deficiency closed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Celularity on Sept 2, 2025 that it has regained compliance with Listing Rule 5250(c)(1).","Compliance determination based on the Aug 29, 2025 filing of Q1 2025 10-Q and Q2 2025 10-Q.","Listing Rule 5250(c)(1) requires timely filing of periodic financial reports.","The previously reported deficiency is now closed, removing immediate delisting risk.","Celularity is now current with its SEC periodic filings through June 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141164,"accession_number":"0001641172-25-024623","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Celularity retires all $41.6M senior secured debt via IP sale and license-back deal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Retired all $32M principal plus $9.6M accrued interest on senior secured loans for total $41.6M.","Sold IP assets to Celeniv for $33,812,230; licensed back exclusively with five-year repurchase option.","Created four operating subsidiaries for advanced biomaterials, longevity cell therapy, biobanking, and CDMO.","Proceeds used to retire $27M RWI loan and $6,812,230 promissory note; prior note proceeds retired C.V. Starr loan.","Retained exclusive use of IP; balance sheet improved with removal of general security interest."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141163,"accession_number":"0001641172-25-023231","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Celularity invests $2.9M in Defeye preferred stock; gets Nasdaq extension to Aug 31 for late filings","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Acquired 7,198.6 shares of Defeye Series Seed-2 Preferred Stock for $2.89M in product purchase credits.","Received Nasdaq notice of non-compliance for late Q1 2025 10-Q filing; submitted compliance plan.","Nasdaq extended deadline to Aug 31, 2025 to file both Q1 and Q2 10-Qs; risk of delisting if missed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141162,"accession_number":"0001641172-25-021831","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Celularity issues $6.81M promissory note and warrant to investor Lim Kok Thay","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $6,812,230 promissory note to Lim Kok Thay, 2% interest, matures March 21, 2026, secured by all company assets.","Issued warrant to purchase 3,700,000 shares of Class A common stock at $2.528/share, exercisable for 5 years.","Proceeds partly used to repay principal and accrued interest on C.V. Starr & Co. loan from March 2023.","The note and warrant were issued in unregistered transactions under exemption from registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141161,"accession_number":"0001641172-25-021556","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Celularity raises $2M via private placement of 1.23M shares and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 1,230,769 shares of common stock and warrants to purchase 1,230,769 shares at $1.625 per unit.","Gross proceeds of $2M; net proceeds for working capital and general corporate purposes.","Warrants exercisable at $1.50 per share for two years from issuance date.","Private placement to an institutional investor; securities unregistered under Section 4(a)(2) and Regulation D.","Closing occurred on July 14, 2025; customary representations and warranties included."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141159,"accession_number":"0001641172-25-021378","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K/A","filed_at":"2025-07-29T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Celularity reprices warrants for Starr and RWI, issues new warrants under forbearance amendments","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Repriced Starr warrants to $1.692/share; issued new warrant for 100,000 shares.","Repriced RWI warrants to $2.844/share; issued new warrant for 500,000 shares.","Warrant amendments and issuances executed under February 2025 binding term sheets.","Filed amended warrants for prior issuances dating from March 2023 to March 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141160,"accession_number":"0001641172-25-020580","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2025-07-22T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Celularity raises $1.035M in private placement of 739,286 shares at $1.40/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issue and sale of 739,286 shares of Class A common stock at $1.40 per share for gross proceeds of $1,035,000.","Warrant adjustment: exercise price of 1,311,093 warrants revised to $2.50 and expiration extended to June 30, 2030.","Closing expected during week of July 21, 2025; net proceeds to be used for working capital and general corporate purposes.","Securities offered in a private placement under Section 4(a)(2) and/or Regulation D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158967,"accession_number":"0001641172-25-014525","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2025-06-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Celularity terminates CFO Beers without cause; names DosSantos interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO David Beers terminated without cause effective June 10, 2025; severance subject to release.","Termination not related to financial/operating results or reporting disagreements.","Joseph DosSantos (SVP Finance) appointed interim CFO; no additional compensation.","Company retained CFO Squad for outsourced accounting, SEC reporting, and consulting support.","Search for a permanent CFO is underway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158966,"accession_number":"0001641172-25-014073","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Celularity appoints Vincent LeVien as Class II director, effective June 5, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Vincent LeVien appointed to Board as Class II director, serving until 2026 Annual Meeting.","Appointed to Audit Committee and Nominating & Corporate Governance Committee.","LeVien is Chairman and CEO of I Got a Guy, Inc., a network consulting firm.","No material arrangements or related-party transactions with the new director."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158965,"accession_number":"0001641172-25-011751","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["1.01","3.02"],"status":"ready","headline":"Celularity extends convertible note maturity to Aug 15, 2025; issues 100K shares","summary_kind":"llm","event_type":"debt","confidence":"medium","bullets":["Maturity of Convertible Promissory Note (dated March 13, 2024) extended from May 12, 2025 to August 15, 2025.","Issued 100,000 restricted common shares to YA II PN, Ltd. as consideration for the extension.","The shares carry piggyback registration rights for inclusion in future registration statements.","No principal amount or conversion rate of the note was disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158964,"accession_number":"0001641172-25-011253","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Dean Kehler resigns from Celularity board effective May 14, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dean Kehler resigned as a director of Celularity Inc. on May 14, 2025.","The resignation was not related to any disagreement with the company.","No replacement director has been announced or appointed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158963,"accession_number":"0001641172-25-009462","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Celularity reports 2024 revenue of $54.2M, up 138% YoY; operating loss narrows 80%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues $54.2M, up 138.1% YoY; product sales in wound care up 168.7% to $35.3M.","Operating expenses fell 57% to $92.6M; loss from operations improved 80.1% to $38.4M.","Received FDA Tissue Reference Group recommendation letters for new placental-derived biomaterial products.","Cash and cash equivalents $738K at Dec 31, 2024, up from $227K prior year.","Total assets $132.7M; stockholders' equity $8.8M at year-end 2024."],"consensus_eps_estimate":-0.765,"consensus_eps_actual":-0.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":11426000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158962,"accession_number":"0001641172-25-008104","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Celularity regains Nasdaq compliance after paying $70,000 past due fee","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On April 30, 2025, Nasdaq notified Celularity that its $70,000 past due fee was paid.","Company has regained compliance with Nasdaq Listing Rule 5250(f); matter closed.","No further action required; listing on Nasdaq continues with both CELU and CELUW."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158961,"accession_number":"0001641172-25-005884","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2025-04-23T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Celularity receives Nasdaq notice for late 10-K filing; must submit compliance plan by June 16, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Failed to file 2024 Form 10-K by extension deadline; Nasdaq issued notice of non-compliance on April 16, 2025.","Must submit plan to regain compliance within 60 days (by June 16, 2025) or face potential delisting.","If plan accepted, Celularity has until October 13, 2025 to comply; expects to file 10-K imminently.","No immediate effect on trading under CELU and CELUW.","No guarantee of regaining compliance; delisting risk if plan not accepted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177398,"accession_number":"0001493152-25-011156","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2025-03-21T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Celularity extends note maturity to May 12, 2025; issues 100k shares as forbearance fee","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Extended convertible note maturity from March 13 to May 12, 2025; Yorkville forbears from default until then.","Outstanding obligation of $2,152,602.74 plus accrued interest; issued 100,000 Class A shares as forbearance fee.","Original $3.15M note from March 2024; company had default events (failure to file/effect registration statement).","Shares issued under Section 4(a)(2) exemption with piggyback registration rights."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177397,"accession_number":"0001493152-25-007986","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Celularity enters manufacturing collaboration with BlueSphere Bio for AML cell therapy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Master Services Collaboration Agreement to manufacture BlueSphere's TCR T cell therapies for AML.","Work to be performed at Celularity's 37,000 sq ft Florham Park cGMP facility; dedicated staff and small portion of footprint used.","BlueSphere's second cell therapy product for AML will be produced; BlueSphere retains oversight.","Celularity CEO highlights revenue potential of leveraging manufacturing infrastructure for third-party clients.","BlueSphere expects to dose first patient in TCX-101 program in 1H2025 and file IND for TCX-102 in Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177396,"accession_number":"0001493152-25-007097","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Celularity extends loan maturities to Feb 2026 via binding term sheets with RWI and Starr","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["RWI binding term sheet covers three loans totaling $27M principal; maturity extended to Feb 15, 2026.","Starr binding term sheet extends $5M loan (net $100K OID) maturity to Feb 15, 2026.","Company to pay ~$1.3M (RWI) and ~$0.8M (Starr) in past-due interest from next public offering proceeds.","New five-year warrants to be issued: 500k shares to RWI, 100k shares to Starr, exercise price min $1.50.","Existing RWI and Starr warrants repriced at 90% of future closing price, floor $1.50."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177395,"accession_number":"0001493152-25-003722","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2025-01-27T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Celularity amends warrant exercise price to $2.07, receives $2.46M gross proceeds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended exercise price of two warrants from $2.49 to $2.07 per share on January 24, 2025.","Holder exercised warrants for 1,188,255 shares of Class A common stock, gross proceeds ~$2.46M.","2020 warrant shares registered under S-1; 2024 warrant shares not yet registered.","Proceeds provide additional capital for the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177394,"accession_number":"0001493152-25-003635","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2025-01-24T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Celularity private placement terminated after investor fails to pay subscription amount","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Celularity terminated securities purchase agreement with institutional investor for 1,263,157 shares and warrants at $2.375/share.","On Jan 23, 2025, notified investor that agreement expired due to non-receipt of subscription amount.","The previously announced private placement will not be consummated.","The agreement was initially disclosed on January 3, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177393,"accession_number":"0001493152-25-000294","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2025-01-03T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Celularity raises $3.0M via private placement of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 1,263,157 shares of Class A common stock and warrants to purchase up to 1,263,157 shares at $2.375 per unit.","Warrants exercisable after 6 months at $2.97 per share, expire 5 years from issuance.","Gross proceeds of $3.0M; closing expected during week of January 6, 2025.","Net proceeds will be used for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194144,"accession_number":"0001493152-24-050885","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Celularity stockholders elect Robert J. Hariri as Class III director and ratify EisnerAmper as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Robert J. Hariri elected with 10,250,294 votes for; 53,960 withheld; 3,285,202 broker non-votes.","Ratification of EisnerAmper LLP as independent auditor passed: 13,561,068 for, 24,211 against, 4,177 abstentions.","Annual meeting held December 19, 2024; two proposals voted on as described in proxy statement filed November 19, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194143,"accession_number":"0001493152-24-048330","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2024-12-02T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Celularity raises up to $1M via convertible notes and warrants; initial $500K closed","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $500,000 in 8% unsecured senior convertible notes due one year; interest rises to 10% on default.","Notes convertible into common stock at $2.85/share (floor $1.00) upon default or subsequent financing of ≥$2.5M.","Purchaser warrants cover 100% of subscription amount at $2.85 exercise price, 5-year term, with one-time reset floor $1.00.","Proceeds earmarked for working capital and general corporate purposes.","Placement agent Madison Global receives 7% cash fee, 1% expense allowance, and warrants at 125% of offering price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194142,"accession_number":"0001493152-24-048082","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2024-11-29T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Celularity receives Nasdaq delisting notice for late Q3 2024 10-Q filing","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Failed to file Q3 2024 10-Q by Nov 19 extension; Nasdaq issued non-compliance notice on Nov 21, 2024.","No immediate effect on CELU/CELUW trading; must submit compliance plan by Jan 20, 2025.","If plan accepted, compliance deadline extended to May 13, 2025. No assurance of regaining compliance.","Delay attributed to incomplete preparation of financial statements for Q3 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194141,"accession_number":"0001493152-24-044292","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Celularity sets 2024 annual meeting for Dec 19; record date Nov 8","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2024 Annual Meeting of Stockholders scheduled for December 19, 2024.","Record date for voting is November 8, 2024.","Stockholder proposals for inclusion in proxy must be received by November 18, 2024.","Meeting date differs by more than 30 days from 2023 meeting (June 14, 2023)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194140,"accession_number":"0001493152-24-043924","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Celularity raises FY 2024 net sales guidance to $54-60M; October sales hit record $8.3-8.9M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raises full-year 2024 expected net sales guidance to $54M-$60M from $50M-$56M, citing strong advanced biomaterial sales.","Expected net sales through October 31, 2024: $44.4M ($40.2M advanced biomaterials, $4.2M biobanking); includes ~$9M from new Rebound product.","October 2024 expected net sales of $8.3M-$8.9M marks highest-ever single-month figure.","Filed Q2 2024 Form 10-Q on Nov 6, resolving Nasdaq non-compliance notice from Oct 16, 2024.","Advanced biomaterial product sales for first half 2024 exceeded $24M, surpassing full-year 2023 total."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194139,"accession_number":"0001493152-24-042525","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2024-10-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Celularity expects H1 2024 biomaterial revenue >$24M, Rebound >$9M; reaffirms $50-56M FY guidance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary net revenue from biomaterial products exceeds $24M for six months ended June 30, 2024, surpassing full-year 2023 sales.","Acquired Rebound allograft matrix from Sequence LifeScience; generated >$9M in net revenue to date, reimbursed via HCPCS Q4296.","Reaffirms FY 2024 combined net sales guidance of $50-56M for biomaterial and biobanking businesses.","Plans to file Q2 2024 10-Q in coming weeks; working to regain Nasdaq listing compliance.","Product pipeline: Celularity Tendon Wrap 510(k) submission expected early 2025, FUSE Bone Void Filler H2 2025, Placental Matrix 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194138,"accession_number":"0001493152-24-041706","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2024-10-21T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Celularity faces Nasdaq suspension Oct 25 for delinquent 10-Q filings; plans appeal","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Celularity on Oct 16, 2024, that trading will be suspended Oct 25 due to failure to file Q1 and Q2 2024 10-Qs by Oct 14 extension deadline.","Celularity intends to appeal Nasdaq's determination by Oct 23, 2024, under Listing Rule 5800 Series.","If appeal is filed, trading continues during appeal process; no assurance of success in regaining compliance.","Previously, on Aug 22, 2024, Nasdaq notified Celularity of non-compliance; exception granted until Oct 14, but forms still not filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194137,"accession_number":"0001493152-24-041330","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2024-10-16T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Celularity acquires Rebound placental matrix product from Sequence LifeScience for $5.5M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total consideration $5.5M: $1M upfront cash, up to $4M monthly milestone payments (20% of net sales), and $500K credit.","Exclusive supply agreement with Sequence for min 6 months; Celularity intends to transfer manufacturing in-house.","H1 2024 biomaterial sales >$24M, exceeding full year 2023; Rebound expected to contribute in Q4 2024.","Rebound is full-thickness placental-derived allograft matrix for wound care and soft tissue repair."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210460,"accession_number":"0001493152-24-036234","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2024-09-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Celularity CMO Adrian Kilcoyne resigns effective August 6, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Adrian Kilcoyne, EVP and Chief Medical Officer, resigns to pursue other opportunities.","Resignation effective August 6, 2024; no successor announced.","No disagreement with Celularity cited; departure unrelated to operations or policies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210459,"accession_number":"0001493152-24-034216","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2024-08-28T23:59:59+00:00","items":["5.02","7.01","8.01","9.01"],"status":"ready","headline":"Celularity appoints Richard J. Berman to Board; reduces board from 7 to 6","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Richard J. Berman appointed as Class II director, effective Aug 27, 2024, to fill vacancy left by Robin L. Smith.","Berman received an option to purchase 118,111 shares at $3.01/share, vesting in three equal annual installments.","Board reduced from seven to six directors following Marc Mazur's departure; Class III reduced from two to one.","Berman brings over 40 years of VC and M&A experience; served on boards of six companies over $1B market value.","He was appointed to the Audit Committee; qualifies as independent under Nasdaq rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210458,"accession_number":"0001493152-24-033763","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2024-08-23T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Celularity receives Nasdaq delisting notice for late Q2 2024 10-Q and continued Q1 2024 10-Q delinquency","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Celularity on Aug 22, 2024 of non-compliance with Listing Rule 5250(c)(1) due to failure to timely file Q2 2024 10-Q and continued delinquency in Q1 2024 10-Q.","Celularity must submit a compliance plan by September 6, 2024; if accepted, has until October 14, 2024 to implement.","Listing on Nasdaq Capital Market continues under CELU and CELUW without immediate effect.","Celularity intends to submit a plan but cautions no assurance of acceptance or future compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210457,"accession_number":"0001493152-24-030288","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["4.01","5.02","9.01"],"status":"ready","headline":"Celularity dismisses Deloitte as auditor, engages EisnerAmper; director Marc Mazur resigns","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Deloitte & Touche dismissed as independent auditor effective Aug 2, 2024; prior reports contained going concern explanatory paragraph.","EisnerAmper LLP engaged as new auditor for FY 2024; will review interim Q1 and Q2 2024 financials.","Board member Marc Mazur resigned effective July 31, 2024; no disagreement with company.","No disagreements or reportable events occurred during Deloitte's engagement through dismissal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228788,"accession_number":"0001493152-24-021404","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Celularity receives Nasdaq delisting notice for late Q1 2024 10-Q and 2023 10-K","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Celularity on May 21, 2024 of non-compliance with Listing Rule 5250(c)(1) for delinquent Q1 2024 10-Q and 2023 10-K.","No immediate delisting; CELU and CELUW continue trading on Nasdaq Capital Market.","Celularity must submit a compliance plan by June 17, 2024; if accepted, has until October 14, 2024 to implement.","Delay in completing the 2023 Form 10-K caused the Q1 2024 filing delay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228787,"accession_number":"0001493152-24-020832","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2024-05-21T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Celularity guides Q4 2023 revenue ~$12.1M, Q1 2024 revenue ~$14.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2023 net revenue ~$12.1M from biomaterial product sales and biobanking services.","Preliminary Q1 2024 net revenue ~$14.8M from the same segments, up ~22% sequentially.","Full-year 2023 and Q1 2024 financials not yet finalized; subject to audit/review adjustments.","Company hosted an Investor & R&D Day on May 21, 2024, with presentation posted on IR website."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":14681000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228786,"accession_number":"0001493152-24-015455","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2024-04-22T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Celularity receives Nasdaq delisting notice for late 10-K filing; must submit plan by June 17","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Failed to file 2023 Form 10-K by April 15 extension; Nasdaq notified on April 17, 2024.","Common stock (CELU) and warrants (CELUW) continue trading; no immediate delisting.","Must submit compliance plan within 60 days (by June 17, 2024); if accepted, cure by Oct 14, 2024.","No assurance of regaining compliance; delisting possible if plan not accepted or cure fails."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247439,"accession_number":"0001493152-24-010134","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2024-03-15T23:59:59+00:00","items":["1.01","2.03","3.02","3.03","9.01"],"status":"ready","headline":"Celularity signs $10M standby equity deal and $3.15M convertible note with Yorkville","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["SEPA allows Celularity to sell up to $10M of common stock to Yorkville over 36 months at 97% of VWAP.","Yorkville provides $3.15M convertible note (8% interest, matures Mar 13, 2025) with conversion price initially $6.3171, resets to VWAP floor $2.4898.","Existing lenders RWI and Starr forbear defaults in exchange for 100bps interest increase and warrants (RWI: 300k shares at $5.895; Starr: reprice to $5.895).","Registration statement for Yorkville resale to be filed by May 3, 2024; no advances or conversions until effective.","Proceeds used for working capital; issuance capped at 19.99% of outstanding shares under Nasdaq rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247438,"accession_number":"0001493152-24-007848","cik":1752828,"company_name":"Celularity Inc","ticker":"CELU","form_type":"8-K","filed_at":"2024-02-26T23:59:59+00:00","items":["3.03","5.03","5.07","9.01"],"status":"ready","headline":"Celularity approves 1-for-10 reverse stock split; warrant issuance to RWI fails","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board set reverse split ratio at 1-for-10, effective 5:00 PM ET on Feb 28, 2024.","Post-split shares outstanding expected ~21.8M (excluding fractional shares).","Proposal to issue Tranche 2 Warrants to Resorts World Inc (RWI) failed: 66.4M for, 0.96M against.","Stockholders also approved adjournment proposal with 134.2M votes for.","Cash paid in lieu of fractional shares based on Feb 28 closing price adjusted by split ratio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":26488448.48165905,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-02-26T23:59:59+00:00|247438"}